Compare Gilead Sciences, Inc. (GILD) vs Direxion Daily TSLA Bull 2X Shares (TSLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Direxion Daily TSLA Bull 2X Shares — how do they compare? Gilead Sciences, Inc. trades at $135.26 (market cap $164.99B), while Direxion Daily TSLA Bull 2X Shares trades at $8.37. The key difference: Gilead Sciences, Inc. pays a 2.47% dividend while Direxion Daily TSLA Bull 2X Shares pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, Direxion Daily TSLA Bull 2X Shares nearer its low. Which is the better fit depends on your goals.
| GILD | TSLL | |
|---|---|---|
Market Cap | $164.99B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $155.80 | $23.03 |
52-Week Low | $110.56 | $6.74 |
Enterprise Value | $188.06B | — |
Dividend Yield | 2.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.21, up 1.8% in the last session, with a bullish technical outlook and strong analyst support. Recent Q2 2026 results showed a revenue beat despite a net loss driven by acquisition costs, with HIV drug sales and pipeline progress fueling raised full-year guidance. The stock exhibits robust cash flow from operations and a high gross margin, though negative net income and elevated debt levels present fundamental concerns.
The outlook is positive based on raised sales guidance and pipeline momentum, but risks include patent cliffs for key HIV drugs by the mid-2030s and integration challenges from recent acquisitions. With a consensus price target of $151.22 implying 13.5% upside, Wall Street sentiment is bullish, though investors should weigh growth prospects against execution and regulatory risks.
TSLL, the Direxion Daily TSLA Bull 2X Shares ETF, trades at $8.11, up 5.6% today. Technical indicators show a mixed picture with a bullish overall signal but bearish moving averages. The ETF, which aims to deliver twice Tesla's daily returns, lacks fundamental metrics as it is a leveraged product. Recent news highlights its volatility and investor focus on Tesla's performance.
The outlook for TSLL is tied to Tesla's stock volatility, offering amplified gains but significant risks. Key opportunities include potential upside from Tesla's growth, while risks involve high volatility and decay from daily rebalancing. Investors should be cautious due to the leveraged structure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Direxion Daily TSLA Bull 2X Shares
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →
